Latest birth defects Stories
The U.S. Food and Drug Administration (FDA) links Topamax® to cleft lip and cleft palate. Houston, Texas (PRWEB) May 13, 2011 The U.S.
In March 2011, the U.S. Food and Drug Administration strengthened its warning against the anti-consulant drug, Topamax, because new data suggests an increased risk of birth defects such as cleft palate or cleft lip.
New research in the FASEB Journal details the first evidence that breakdown products of thalidomide produce the specific, toxic effects of thalidomide in embryos.
Anticonvulsant medications such as Depakote are being found to possibly cause birth defects according to recent studies.
Dilantin is one of the most widely prescribed anticonvulsant drugs on the U.S. market, primarily prescribed to individuals suffering from epilepsy.
Topamax birth defect claims are being investigated across the country as parents may be unknowingly exposing infants to the anticonvulsant drug in utero, possibly increasing the risk of major birth defects.
As the FDA changes the pregnancy category of migraine drug Topamax to a class D drug, worry over the lack of drug testing for birth defects increases. The Wall Street Journal reports on a history of birth defects related to medications and pregnancy.
The Senators Firm announced today that it is offering free confidential case reviews to people who took Topamax during pregnancy and suffered Topamax induced cleft lip, cleft palate, and oral cleft birth defects.
A new report released Monday by the Natural Resources Defense Council documents 42 "disease clusters" in 13 states, each of which includes incidences of numerous types of cancer, birth defects or other chronic diseases.
Topamax Birth Injury Resources (TBIR) is an online resource center dedicated to providing accurate and up-to-date information about the possible birth defects related to the use of the epilepsy drug Topamax.
- Emitting flashes of light; glittering.